Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Experimental Techniques in Urology & Nephrology

Is there Enough Evidence to Support Calcineurin Inhibitor Minimization or Avoidance in Renal Transplantation?

  • Open or Close Althaf MM1*, Abdelsalam MS2 and Wahid M1

    1Jack Pryor renal unit, Norfolk and Norwich University Hospital-NHS Foundation Trust Colney Lane, Norwich, Norfolk, United Kingdom

    2Nephrology Unit, Alexandria University, Alexandria, Egypt

    *Corresponding author:Mohammed Mahdi Althaf, Jack Pryor renal unit, Norwich University Hospital-NHS Foundation Trust Colney Lane, Norwich, Norfolk, United Kingdom

Submission: February 18, 2020; Published: March 06, 2020

DOI: 10.31031/ETUN.2020.03.000554

ISSN: 2578-0395
Volume3 Issue1

Abstract

Renal transplantation is the modality of choice for renal replacement therapy in patients with end-stage renal disease. Following induction immunosuppression, most maintenance immunosuppressive regimens include a calcineurin inhibitor. While this class of immunosuppressive therapy is highly effective it has a toxic effect on the renal allograft termed calcineurin inhibitor toxicity which can contribute to graft loss over time. Thus, their minimization, withdrawal or avoidance is of interest to transplant clinicians as well to renal transplant recipients. This mini review takes an in-depth review and analysis of all published data in this field.

Keywords: Calcineurin inhibitor; Renal transplant; Kidney transplant

Abbreviations: CNI: Calcineurin Inhibitors; SRL: Sirolimus; ESRD: End Stage Renal Disease; CAN: Chronic allograft nephropathy; DFG: Death with functioning graft; mTORi: Mammalian Target of Rapamycin Inhibitors; CsA: Cyclosporine; TAC: Tacrolimus; MMF: Mycophenolate Mofetil; AZA: Azathioprine; BPAR: Biopsy Proven Acute Rejection

Get access to the full text of this article